<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04890262</url>
  </required_header>
  <id_info>
    <org_study_id>Vedolizumab-4035</org_study_id>
    <nct_id>NCT04890262</nct_id>
  </id_info>
  <brief_title>A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real-World Practice</brief_title>
  <acronym>VARIETY-AUT</acronym>
  <official_title>Prospective, Non-interventional, Observational Study in Patients With IBD Receiving IV or SC Vedolizumab Therapy to Observe Route of Administration Choices and Outcomes (VARIETY-AUT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vedolizumab is a medicine that helps to reduce symptoms of IBD and the associated&#xD;
      inflammation in the digestive system for participants with ulcerative colitis or Crohn's&#xD;
      disease.&#xD;
&#xD;
      In this study, participants with ulcerative colitis or Crohn's disease will be treated with&#xD;
      vedolizumab according to their clinic's standard practice. Participants will receive&#xD;
      vedolizumab as either an infusion or an injection just under the skin (subcutaneous). The&#xD;
      main aim of the study is to observe real-world treatment patterns in participants treated&#xD;
      with vedolizumab.&#xD;
&#xD;
      The study sponsor will not be involved in how participants are treated but will provide&#xD;
      instructions on how the clinics will record what happens during the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-interventional, prospective study of participants with moderately to severely&#xD;
      active IBD (UC or CD) who are initiating or currently ongoing induction or maintenance&#xD;
      treatment with vedolizumab in the real world setting.&#xD;
&#xD;
      The study will enroll approximately 100 participants. The data will be collected&#xD;
      prospectively at the study sites and will be recorded into electronic case report forms&#xD;
      (e-CRFs). All the participants will be assigned to a single observational cohort:&#xD;
&#xD;
        -  Participants with IBD&#xD;
&#xD;
      This multi-center study will be conducted in Austria at specialized gastroenterology centers.&#xD;
      The overall duration of the study will be 24 months. Data will be collected at baseline, at 3&#xD;
      months after induction, and every 6 months after induction, and at the time of switch,&#xD;
      discontinuation and/or at routine follow-up visits up to 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2021</start_date>
  <completion_date type="Anticipated">August 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 29, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Persisting on Treatment With Vedolizumab IV Compared to Participants With Treatment Change up to 12 Months</measure>
    <time_frame>Baseline up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to any Treatment Change</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Reason for Treatment Change</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Change in Vedolizumab Dosing Frequency</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Vedolizumab Treatment</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Changed to Another Treatment</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Crohns Disease</condition>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>Participants With Inflammatory Bowel Disease (IBD)</arm_group_label>
    <description>Participants diagnosed with moderately to severely active IBD (UC or CD) who are currently ongoing vedolizumab intravenous (IV) treatment in line with current Summary of Product Characteristics (SmPC) or local prescribing information with the option to switch to vedolizumab subcutaneous (SC) treatment, will be observed prospectively for 24 months.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult participants with moderately to severely active UC or CD receiving vedolizumab&#xD;
        treatment in accordance with the approved SmPC.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Has moderately to severely active IBD (UC or CD), initiating or ongoing IV induction&#xD;
        treatment with vedolizumab in accordance with the current SmPC at baseline OR IBD&#xD;
        participants receiving ongoing/maintenance IV vedolizumab treatment, with the option to&#xD;
        switch to SC vedolizumab maintenance treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior history of intolerability, hypersensitivity, or other contraindications (active&#xD;
             severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and&#xD;
             opportunistic infections such as Progressive Multifocal Leukoencephalopathy) to&#xD;
             vedolizumab therapy as defined in the current SmPC.&#xD;
&#xD;
          2. Current or planned participation in an interventional clinical trial for CD or UC.&#xD;
&#xD;
          3. Cognitive incapacity, unwillingness or language barriers precluding adequate&#xD;
             understanding or cooperation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Contact</last_name>
    <phone>+1877-825-3327</phone>
    <email>medinfoUS@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medizinische Universitat Graz, Innere Medizin</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+43 31638581786</phone>
      <email>christoph.hoegenauer@medunigraz.at</email>
    </contact>
    <investigator>
      <last_name>Christoph Hogenauer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Innsbruck, Innere Medizin I</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+43 51250423539</phone>
      <email>robert.koch@i-med.ac.at</email>
    </contact>
    <investigator>
      <last_name>Robert Koch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JKU Linz, Innere Medizin</name>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+43 57680836120</phone>
      <email>alexander.moschen@kepleruniklinikum.at</email>
    </contact>
    <investigator>
      <last_name>Alexander Moschen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Darmpraxis Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+43 6645318760</phone>
      <email>info@darmpraxis.at</email>
    </contact>
    <investigator>
      <last_name>Thomas Haas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Bruder</name>
      <address>
        <city>St. Veit/Glan</city>
        <zip>9300</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+43 42124998507</phone>
      <email>karin.steidl@bbstveit.at</email>
    </contact>
    <investigator>
      <last_name>Karin Steidl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+43 72424152181</phone>
      <email>harald.hofer@klinikum-wegr.at</email>
    </contact>
    <investigator>
      <last_name>Harald Hofer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Wien, Innere Medizin III</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+43 14040062450</phone>
      <email>christian.primas@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Christian Primas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/60a50c041f1122001e30a7db</url>
    <description>To obtain more information on the study, click here/on this link.</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 13, 2021</study_first_submitted>
  <study_first_submitted_qc>May 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

